Some companies picked up major regulatory nods. Others experienced major regulatory setbacks.
Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from, but here are 10 big ones that stood out:Dexcom G7 receives FDA clearance
The long-awaited regulatory nod for Dexcom’s next-generation continuous glucose monitor (CGM) finally came in December.
Some suggested that San Diego-based Dexcom may pick up clearance as soon as summer 2022. However, a software change recommended by the FDA, plus COVID-19-related backlog, delayed proceedings.
Dexcom COO Ja…